Neuroblastoma Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Combination Chemotherapy, Monoclonal Antibody Therapy, Vaccine Therapy, Chimeric Antigen Receptor T-Cell Immunotherapy, Oncolytic Virus Therapy), By Application (Hospitals, Clinics, Others), Regional Insights and Forecast From 2026 To 2035

Detailed TOC of Global and United States Neuroblastoma Treatment Market Report & Forecast 2022-2035

1 Study Coverage
1.1 Neuroblastoma Treatment Revenue in Neuroblastoma Treatment Business (2017-2022) & (US$ Million) Introduction
1.2 Global Neuroblastoma Treatment Outlook 2017 VS 2022 VS 2035
1.2.1 Global Neuroblastoma Treatment Market Size for the Year 2017-2035
1.2.2 Global Neuroblastoma Treatment Market Size for the Year 2017-2035
1.3 Neuroblastoma Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2035
1.3.1 The Market Share of United States Neuroblastoma Treatment in Global, 2017 VS 2022 VS 2035
1.3.2 The Growth Rate of Neuroblastoma Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2035
1.4 Neuroblastoma Treatment Market Dynamics
1.4.1 Neuroblastoma Treatment Industry Trends
1.4.2 Neuroblastoma Treatment Market Drivers
1.4.3 Neuroblastoma Treatment Market Challenges
1.4.4 Neuroblastoma Treatment Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Neuroblastoma Treatment by Type
2.1 Neuroblastoma Treatment Market Segment by Type
2.1.1 Combination Chemotherapy
2.1.2 Monoclonal Antibody Therapy
2.1.3 Vaccine Therapy
2.1.4 Chimeric Antigen Receptor T-Cell Immunotherapy
2.1.5 Oncolytic Virus Therapy
2.2 Global Neuroblastoma Treatment Market Size by Type (2017, 2022 & 2035)
2.3 Global Neuroblastoma Treatment Market Size by Type (2017-2035)
2.4 United States Neuroblastoma Treatment Market Size by Type (2017, 2022 & 2035)
2.5 United States Neuroblastoma Treatment Market Size by Type (2017-2035)
3 Neuroblastoma Treatment by Application
3.1 Neuroblastoma Treatment Market Segment by Application
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Neuroblastoma Treatment Market Size by Application (2017, 2022 & 2035)
3.3 Global Neuroblastoma Treatment Market Size by Application (2017-2035)
3.4 United States Neuroblastoma Treatment Market Size by Application (2017, 2022 & 2035)
3.5 United States Neuroblastoma Treatment Market Size by Application (2017-2035)
4 Global Neuroblastoma Treatment Competitor Landscape by Company
4.1 Global Neuroblastoma Treatment Market Size by Company
4.1.1 Top Global Neuroblastoma Treatment Companies Ranked by Revenue (2021)
4.1.2 Global Neuroblastoma Treatment Revenue by Player (2017-2022)
4.2 Global Neuroblastoma Treatment Concentration Ratio (CR)
4.2.1 Neuroblastoma Treatment Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Neuroblastoma Treatment in 2021
4.2.3 Global Neuroblastoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Neuroblastoma Treatment Headquarters, Revenue in Neuroblastoma Treatment Business (2017-2022) & (US$ Million) Type
4.3.1 Global Neuroblastoma Treatment Headquarters and Area Served
4.3.2 Global Neuroblastoma Treatment Companies Revenue in Neuroblastoma Treatment Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Neuroblastoma Treatment Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Neuroblastoma Treatment Market Size by Company
4.5.1 Top Neuroblastoma Treatment Players in United States, Ranked by Revenue (2021)
4.5.2 United States Neuroblastoma Treatment Revenue by Players (2020, 2021 & 2022)
5 Global Neuroblastoma Treatment Market Size by Region
5.1 Global Neuroblastoma Treatment Market Size by Region: 2017 VS 2022 VS 2035
5.2 Global Neuroblastoma Treatment Market Size by Region (2017-2035)
5.2.1 Global Neuroblastoma Treatment Market Size by Region: 2017-2022
5.2.2 Global Neuroblastoma Treatment Market Size by Region (2023-2035)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Neuroblastoma Treatment Market Size YoY Growth 2017-2035
6.1.2 North America Neuroblastoma Treatment Market Facts & Figures by Country (2017, 2022 & 2035)
6.1.3 United States
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Neuroblastoma Treatment Market Size YoY Growth 2017-2035
6.2.2 Asia-Pacific Neuroblastoma Treatment Market Facts & Figures by Region (2017, 2022 & 2035)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe Neuroblastoma Treatment Market Size YoY Growth 2017-2035
6.3.2 Europe Neuroblastoma Treatment Market Facts & Figures by Country (2017, 2022 & 2035)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Neuroblastoma Treatment Market Size YoY Growth 2017-2035
6.4.2 Latin America Neuroblastoma Treatment Market Facts & Figures by Country (2017, 2022 & 2035)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Neuroblastoma Treatment Market Size YoY Growth 2017-2035
6.5.2 Middle East and Africa Neuroblastoma Treatment Market Facts & Figures by Country (2017, 2022 & 2035)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Seattle Children?s
7.1.1 Seattle Children?s Company Details
7.1.2 Seattle Children?s Business Overview
7.1.3 Seattle Children?s Neuroblastoma Treatment Introduction
7.1.4 Seattle Children?s Revenue in Neuroblastoma Treatment Business (2017-2022)
7.1.5 Seattle Children?s Recent Development
7.2 CureSearch
7.2.1 CureSearch Company Details
7.2.2 CureSearch Business Overview
7.2.3 CureSearch Neuroblastoma Treatment Introduction
7.2.4 CureSearch Revenue in Neuroblastoma Treatment Business (2017-2022)
7.2.5 CureSearch Recent Development
7.3 Texas Children?s
7.3.1 Texas Children?s Company Details
7.3.2 Texas Children?s Business Overview
7.3.3 Texas Children?s Neuroblastoma Treatment Introduction
7.3.4 Texas Children?s Revenue in Neuroblastoma Treatment Business (2017-2022)
7.3.5 Texas Children?s Recent Development
7.4 NANT
7.4.1 NANT Company Details
7.4.2 NANT Business Overview
7.4.3 NANT Neuroblastoma Treatment Introduction
7.4.4 NANT Revenue in Neuroblastoma Treatment Business (2017-2022)
7.4.5 NANT Recent Development
7.5 Sino Biopharmaceutical
7.5.1 Sino Biopharmaceutical Company Details
7.5.2 Sino Biopharmaceutical Business Overview
7.5.3 Sino Biopharmaceutical Neuroblastoma Treatment Introduction
7.5.4 Sino Biopharmaceutical Revenue in Neuroblastoma Treatment Business (2017-2022)
7.5.5 Sino Biopharmaceutical Recent Development
7.6 Jiangsu Hengrui Medicine Co.,Ltd.
7.6.1 Jiangsu Hengrui Medicine Co.,Ltd. Company Details
7.6.2 Jiangsu Hengrui Medicine Co.,Ltd. Business Overview
7.6.3 Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Introduction
7.6.4 Jiangsu Hengrui Medicine Co.,Ltd. Revenue in Neuroblastoma Treatment Business (2017-2022)
7.6.5 Jiangsu Hengrui Medicine Co.,Ltd. Recent Development
7.7 Fosun Pharmaceutical
7.7.1 Fosun Pharmaceutical Company Details
7.7.2 Fosun Pharmaceutical Business Overview
7.7.3 Fosun Pharmaceutical Neuroblastoma Treatment Introduction
7.7.4 Fosun Pharmaceutical Revenue in Neuroblastoma Treatment Business (2017-2022)
7.7.5 Fosun Pharmaceutical Recent Development
7.8 Novartis
7.8.1 Novartis Company Details
7.8.2 Novartis Business Overview
7.8.3 Novartis Neuroblastoma Treatment Introduction
7.8.4 Novartis Revenue in Neuroblastoma Treatment Business (2017-2022)
7.8.5 Novartis Recent Development
7.9 Juno Therapeutics
7.9.1 Juno Therapeutics Company Details
7.9.2 Juno Therapeutics Business Overview
7.9.3 Juno Therapeutics Neuroblastoma Treatment Introduction
7.9.4 Juno Therapeutics Revenue in Neuroblastoma Treatment Business (2017-2022)
7.9.5 Juno Therapeutics Recent Development
7.10 Kite Pharma
7.10.1 Kite Pharma Company Details
7.10.2 Kite Pharma Business Overview
7.10.3 Kite Pharma Neuroblastoma Treatment Introduction
7.10.4 Kite Pharma Revenue in Neuroblastoma Treatment Business (2017-2022)
7.10.5 Kite Pharma Recent Development
7.11 Adaptimmune
7.11.1 Adaptimmune Company Details
7.11.2 Adaptimmune Business Overview
7.11.3 Adaptimmune Neuroblastoma Treatment Introduction
7.11.4 Adaptimmune Revenue in Neuroblastoma Treatment Business (2017-2022)
7.11.5 Adaptimmune Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer